Cardiac Assist Device for Acute Heart Failure

About CorInnova

CorInnova is pioneering a disruptive approach to mechanical circulatory support with its minimally invasive, non-blood contacting cardiac assist device. Backed by a lead investment from the Wellcome Trust, the company targets the acute heart failure market, seeking to treat patients unsuitable for existing blood-contacting devices. Its technology promises to eliminate risks like thrombosis and stroke, potentially expanding the addressable market to $5 billion. CorInnova is in the preclinical/development stage, building a strong advisory board and securing non-dilutive grant funding.

Therapeutic Areas